PEOPLE - Aprogenex (US) announces the first in a series of management changes:
This article was originally published in Clinica
Executive Summary
Aprogenex (US) has announced the first in a series of management changes during its transition from a development- stage to commercial operations company. An executive committee of three has been formed. For an initial period, the company's founder, Dr Joel Bresser will serve as one of these, having resigned as president & CEO. The remaining two are Walter Cunningham and Terry Ward, both experienced venture capital executives. A search has been initiated for a new CEO and Dr Luis Cantarero has been named acting COO, having been vice-president of R&D since 1994. In addition, Dr Wayne Ryan and Donald Payne have joined the Aprogenex board, replacing Dr Irvin Smith and John Davis.